Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Saved in:

Bibliographic Details
Title:	Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.
Authors:	Laheurte C; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France., Galaine J; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France., Beziaud L; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France., Dosset M; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France., Kerzerho J; CEA, iBiTecS, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), Labex LERMIT, Labex VRI , Gif Sur Yvette, France., Jacquemard C; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431 , Besançon, France., Gaugler B; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France., Ferrand C; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France., Dormoy A; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431 , Besançon, France., Aubin F; Department of Dermatology, University Hospital of Besançon, EA3181, SFR4234 , Besançon cedex, France., Jacoulet P; Department of Pneumology, University Hospital of Besançon , Besançon cedex, France., Westeel V; Department of Pneumology, University Hospital of Besançon , Besançon cedex, France., Borg C; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, INSERM CIC1431, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France; Department of Medical Oncology, University Hospital of Besançon, Besançon cedex, France., Tartour E; INSERM, UMR970, Hôpital Européen Georges Pompidou, Paris, France, Department of Biological Immunology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France, University Paris Descartes , Sorbonne Paris Cité , Paris, France., Godet Y; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France., Maillère B; CEA, iBiTecS, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), Labex LERMIT, Labex VRI , Gif Sur Yvette, France., Adotévi O; INSERM, UMR1098, LabEx LipSTIC, Besançon, France; Univ. Bourgogne Franche-Comté, UMR1098, Besançon, France; Department of Medical Oncology, University Hospital of Besançon, Besançon cedex, France.
Source:	Oncoimmunology [Oncoimmunology] 2016 Feb 18; Vol. 5 (5), pp. e1137416. Date of Electronic Publication: 2016 Feb 18 (Print Publication: 2016).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2162-4011
DOI:	10.1080/2162402X.2015.1137416